MX2022008073A - Anticuerpos dirigidos a los huesos. - Google Patents

Anticuerpos dirigidos a los huesos.

Info

Publication number
MX2022008073A
MX2022008073A MX2022008073A MX2022008073A MX2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A MX 2022008073 A MX2022008073 A MX 2022008073A
Authority
MX
Mexico
Prior art keywords
bones
antibodies directed
antibodies
fragments
poly
Prior art date
Application number
MX2022008073A
Other languages
English (en)
Inventor
Huawei Qiu
Sunghae Park
James Stefano
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2022008073A publication Critical patent/MX2022008073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan anticuerpos recombinantes y conjugados químicamente y fragmentos de los mismos modificados con uno o más péptidos poli-aspartato (poli-D) (p. ej., una secuencia D10) para mejorar la localización de los anticuerpos o fragmentos en hueso. También se describen métodos de fabricación y uso de estos anticuerpos y fragmentos.
MX2022008073A 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos. MX2022008073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20

Publications (1)

Publication Number Publication Date
MX2022008073A true MX2022008073A (es) 2022-07-27

Family

ID=61581744

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.
MX2022008073A MX2022008073A (es) 2017-01-20 2019-07-17 Anticuerpos dirigidos a los huesos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019008549A MX2019008549A (es) 2017-01-20 2018-01-19 Anticuerpos dirigidos a los huesos.

Country Status (17)

Country Link
US (3) US10844115B2 (es)
EP (1) EP3571226A2 (es)
JP (3) JP7227138B2 (es)
KR (3) KR102755284B1 (es)
CN (2) CN118121696A (es)
AR (1) AR110755A1 (es)
AU (1) AU2018210270A1 (es)
BR (1) BR112019013986A2 (es)
CA (1) CA3050884A1 (es)
IL (2) IL317592A (es)
MX (2) MX2019008549A (es)
MY (2) MY194819A (es)
SG (1) SG11201906663VA (es)
TW (3) TW202421659A (es)
UY (1) UY37576A (es)
WO (1) WO2018136698A2 (es)
ZA (1) ZA201907673B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017310344A1 (en) * 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
WO2019232280A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
AU2019301283B2 (en) * 2018-07-10 2024-12-19 Sanofi Combination therapies against cancer targeting CD38 and TGF-beta
US20220010368A1 (en) * 2018-11-19 2022-01-13 Biocartis Nv Enhanced detection of low-copy-number nucleic acids in an integrated workflow
CA3219219A1 (en) 2021-05-07 2022-11-10 Baylor College Of Medicine Treatment of moderate-to-severe osteogenesis imperfecta
JP2024526920A (ja) * 2021-07-20 2024-07-19 ウィリアム マーシュ ライス ユニバーシティ 骨標的療法のための操作された組成物
TW202334209A (zh) * 2021-11-01 2023-09-01 美商健臻公司 成骨不全症之治療
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ554885A (en) 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
CA2688275A1 (en) 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CN115043946A (zh) * 2008-01-03 2022-09-13 斯克里普斯研究院 通过模块识别结构域的抗体靶向
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
CA2745317C (en) * 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
SI2691417T2 (sl) 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
LT2714735T (lt) 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
DK2855527T3 (en) * 2012-05-31 2018-11-26 Innate Pharma TLR3 BINDERS
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
PL2976359T5 (pl) * 2013-03-20 2022-07-18 Genzyme Corporation Sposoby leczenia wrodzonej łamliwości kości
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
FI3083686T4 (fi) 2013-12-17 2023-05-09 Menetelmiä syöpien hoitamiseksi käyttäen pd-1-akselia sitovia antagonisteja ja taksaaneja
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN108136001B (zh) 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
WO2017037634A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof
AU2017310344A1 (en) 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
TW202421659A (zh) * 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途

Also Published As

Publication number Publication date
CN111032690A (zh) 2020-04-17
TWI832600B (zh) 2024-02-11
IL317592A (en) 2025-02-01
EP3571226A2 (en) 2019-11-27
CN111032690B (zh) 2024-03-26
KR20190105236A (ko) 2019-09-16
US20250074975A1 (en) 2025-03-06
IL268114B1 (en) 2025-01-01
JP2023058590A (ja) 2023-04-25
MX2019008549A (es) 2019-09-11
ZA201907673B (en) 2021-05-26
KR20230172039A (ko) 2023-12-21
WO2018136698A2 (en) 2018-07-26
AR110755A1 (es) 2019-05-02
UY37576A (es) 2018-10-31
TWI788321B (zh) 2023-01-01
TW202421659A (zh) 2024-06-01
US20210163584A1 (en) 2021-06-03
JP2020505919A (ja) 2020-02-27
US12098194B2 (en) 2024-09-24
MY207919A (en) 2025-03-27
CN118121696A (zh) 2024-06-04
TW201839013A (zh) 2018-11-01
JP7227138B2 (ja) 2023-02-21
WO2018136698A3 (en) 2018-08-30
IL268114A (en) 2019-09-26
RU2019126026A3 (es) 2021-11-09
MY194819A (en) 2022-12-17
AU2018210270A1 (en) 2019-09-05
US20180208650A1 (en) 2018-07-26
KR102613463B1 (ko) 2023-12-15
JP2025028981A (ja) 2025-03-05
TW202330597A (zh) 2023-08-01
KR20250012197A (ko) 2025-01-23
IL268114B2 (en) 2025-05-01
RU2019126026A (ru) 2021-02-20
JP7597836B2 (ja) 2024-12-10
KR102755284B1 (ko) 2025-01-22
US10844115B2 (en) 2020-11-24
SG11201906663VA (en) 2019-08-27
BR112019013986A2 (pt) 2020-03-03
CA3050884A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
MX2022008073A (es) Anticuerpos dirigidos a los huesos.
PE20220256A1 (es) Sistemas de casx artificiales
CY1124106T1 (el) Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων
ECSP18082207A (es) Neoantígenos y métodos de su uso
MX2019003445A (es) Proteinas de fusion inmunomoduladoras.
UY40283A (es) Método para alterar una propiedad de una planta
PH12020551716A1 (en) Anti-ror antibody constructs
CO2019010503A2 (es) Plataforma de identificación de péptidos inmunogénicos personalizada
MX2020000960A (es) Anticuerpos anti-tigit.
ZA202103511B (en) Engineered robust high tm-phytase clade polypeptides and fragments thereof
MX2019004692A (es) Anticuerpos 4-1bb anti-humano y usos de los mismos.
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
MX2017004664A (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2020004801A (es) Polipeptidos de fusion biespecificos y sus metodos de uso.
PH12021550289A1 (en) Ox40-binding polypeptides and uses thereof
MX2017008660A (es) Polipeptidos enlazados a il-17a.
MX2020003672A (es) Proteinas de fusion inmunomoduladora.
CY1125271T1 (el) Φαρμακο για χρηση στη θεραπεια της ουρικης αρθριτιδας
MX390927B (es) Partículas semejantes a virus recombinantes que utilizan la proteína gag del virus de inmunodeficiencia bovina.
CL2019003167A1 (es) Proteínas de unión al antígeno anti-jagged1.
BR112018075613A2 (pt) peptídeos para o tratamento de osteoartrite
IL277632A (en) CDNF fragments from the carboxyl end, pharmaceutical compositions containing them and their uses
MX2024002130A (es) Metodos y composiciones para mejorar la expresion de proteinas recombinantes.
AR119104A1 (es) Sistemas de casx artificiales
JO3545B1 (ar) تركيبات الناقل-الجسم المضاد وطرق صناعتها واستخدامها